Development and validation of a multidisciplinary risk assessment scale for immune checkpoint inhibitor-associated myocarditis
ObjectiveTo develop a risk assessment scale for immune checkpoint inhibitor (ICI)-associated myocarditis based on multidisciplinary collaboration, and to evaluate its diagnostic performance. MethodsBased on multidisciplinary cooperation, integrating clinical experience from oncology and cardiology,...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shanghai Chinese Clinical Medicine Press Co., Ltd.
2025-08-01
|
| Series: | Zhongguo Linchuang Yixue |
| Subjects: | |
| Online Access: | https://www.c-jcm.com/article/doi/10.12025/j.issn.1008-6358.2025.20250469 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849222995514490880 |
|---|---|
| author | Yanan DAI Yuan LIU Yuchen XU Qingqing CAI Yan WANG Yuhong ZHOU Leilei CHENG Junbo GE |
| author_facet | Yanan DAI Yuan LIU Yuchen XU Qingqing CAI Yan WANG Yuhong ZHOU Leilei CHENG Junbo GE |
| author_sort | Yanan DAI |
| collection | DOAJ |
| description | ObjectiveTo develop a risk assessment scale for immune checkpoint inhibitor (ICI)-associated myocarditis based on multidisciplinary collaboration, and to evaluate its diagnostic performance. MethodsBased on multidisciplinary cooperation, integrating clinical experience from oncology and cardiology, literature data, and patient conditions, a risk assessment scale for ICI-associated myocarditis was developed. A total of 101 patients with malignancies who received immunotherapy at Zhongshan Hospital, Fudan University, from October 2020 to October 2024 were included as the validation cohort. Patients were stratified into low-risk (0-1 point), medium-risk (2-4 points), and high-risk (≥5 points) groups based on their scale scores. The association between pretictive risk stratifications and actual assessment results was assessed using the Cox proportional hazards regression model. The predictive value of the scale for ICI-associated myocarditis was evaluated using receiver operating characteristic (ROC) curve. Agreement between the scale scores and actual assessment results was assessed using Cohen’s Kappa coefficient. ResultsBased on the scale pretictive results, 28(27.7%), 8(7.9%), 65(64.4%) patients were at low risk, medium risk, and high risk for ICI-related myocarditis, respectively; however, 46(45.5%), 8(7.9%), 47(46.5%) were at low risk, medium risk, and high risk actually. Kaplan-Meier survival analysis showed that the cumulative incidence of ICI-related myocarditis in the high-risk group was significantly higher than that in the medium- and low-risk groups (P＜0.05). In the multivariable-adjusted Cox proportional hazards model, the ICI-related myocarditis risk in high-risk group was about 4 times that in the low-risk group. ROC curve analysis demonstrated that the average area under the curve (AUC) for predicting ICI-related myocarditis was 0.81, with an accuracy of 0.74. The Cohen’s Kappa coefficient was 0.55, indicating moderate agreement. In the actual high-risk group, no patient was predicted to be at low risk; in the actual low-risk group, 16 patients were predicted to be at high risk. ConclusionsThis risk assessment scale for ICI-associated myocarditis shows high predictive performance. It provides oncologists with a simple yet effective multidisciplinary diagnostic reference tool, potentially enhancing early identification of ICI-associated myocarditis. |
| format | Article |
| id | doaj-art-47d2f441c85f47ed91ba57321a38863c |
| institution | Kabale University |
| issn | 1008-6358 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Shanghai Chinese Clinical Medicine Press Co., Ltd. |
| record_format | Article |
| series | Zhongguo Linchuang Yixue |
| spelling | doaj-art-47d2f441c85f47ed91ba57321a38863c2025-08-26T01:29:39ZengShanghai Chinese Clinical Medicine Press Co., Ltd.Zhongguo Linchuang Yixue1008-63582025-08-0132456156710.12025/j.issn.1008-6358.2025.2025046920250469Development and validation of a multidisciplinary risk assessment scale for immune checkpoint inhibitor-associated myocarditisYanan DAI0Yuan LIU1Yuchen XU2Qingqing CAI3Yan WANG4Yuhong ZHOU5Leilei CHENG6Junbo GE7Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai Institute of Medical Imaging, Shanghai 200032, ChinaDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, NHC Key Laboratory of Ischemic Heart Diseases, Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, National Clinical Research Center for Interventional Medicine, Shanghai 200032, ChinaDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, NHC Key Laboratory of Ischemic Heart Diseases, Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, National Clinical Research Center for Interventional Medicine, Shanghai 200032, ChinaDepartment of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai Institute of Medical Imaging, Shanghai 200032, ChinaDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, NHC Key Laboratory of Ischemic Heart Diseases, Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, National Clinical Research Center for Interventional Medicine, Shanghai 200032, ChinaObjectiveTo develop a risk assessment scale for immune checkpoint inhibitor (ICI)-associated myocarditis based on multidisciplinary collaboration, and to evaluate its diagnostic performance. MethodsBased on multidisciplinary cooperation, integrating clinical experience from oncology and cardiology, literature data, and patient conditions, a risk assessment scale for ICI-associated myocarditis was developed. A total of 101 patients with malignancies who received immunotherapy at Zhongshan Hospital, Fudan University, from October 2020 to October 2024 were included as the validation cohort. Patients were stratified into low-risk (0-1 point), medium-risk (2-4 points), and high-risk (≥5 points) groups based on their scale scores. The association between pretictive risk stratifications and actual assessment results was assessed using the Cox proportional hazards regression model. The predictive value of the scale for ICI-associated myocarditis was evaluated using receiver operating characteristic (ROC) curve. Agreement between the scale scores and actual assessment results was assessed using Cohen’s Kappa coefficient. ResultsBased on the scale pretictive results, 28(27.7%), 8(7.9%), 65(64.4%) patients were at low risk, medium risk, and high risk for ICI-related myocarditis, respectively; however, 46(45.5%), 8(7.9%), 47(46.5%) were at low risk, medium risk, and high risk actually. Kaplan-Meier survival analysis showed that the cumulative incidence of ICI-related myocarditis in the high-risk group was significantly higher than that in the medium- and low-risk groups (P＜0.05). In the multivariable-adjusted Cox proportional hazards model, the ICI-related myocarditis risk in high-risk group was about 4 times that in the low-risk group. ROC curve analysis demonstrated that the average area under the curve (AUC) for predicting ICI-related myocarditis was 0.81, with an accuracy of 0.74. The Cohen’s Kappa coefficient was 0.55, indicating moderate agreement. In the actual high-risk group, no patient was predicted to be at low risk; in the actual low-risk group, 16 patients were predicted to be at high risk. ConclusionsThis risk assessment scale for ICI-associated myocarditis shows high predictive performance. It provides oncologists with a simple yet effective multidisciplinary diagnostic reference tool, potentially enhancing early identification of ICI-associated myocarditis.https://www.c-jcm.com/article/doi/10.12025/j.issn.1008-6358.2025.20250469immune checkpoint inhibitormyocarditisrisk assessment scalemultidisciplinary diagnosis |
| spellingShingle | Yanan DAI Yuan LIU Yuchen XU Qingqing CAI Yan WANG Yuhong ZHOU Leilei CHENG Junbo GE Development and validation of a multidisciplinary risk assessment scale for immune checkpoint inhibitor-associated myocarditis Zhongguo Linchuang Yixue immune checkpoint inhibitor myocarditis risk assessment scale multidisciplinary diagnosis |
| title | Development and validation of a multidisciplinary risk assessment scale for immune checkpoint inhibitor-associated myocarditis |
| title_full | Development and validation of a multidisciplinary risk assessment scale for immune checkpoint inhibitor-associated myocarditis |
| title_fullStr | Development and validation of a multidisciplinary risk assessment scale for immune checkpoint inhibitor-associated myocarditis |
| title_full_unstemmed | Development and validation of a multidisciplinary risk assessment scale for immune checkpoint inhibitor-associated myocarditis |
| title_short | Development and validation of a multidisciplinary risk assessment scale for immune checkpoint inhibitor-associated myocarditis |
| title_sort | development and validation of a multidisciplinary risk assessment scale for immune checkpoint inhibitor associated myocarditis |
| topic | immune checkpoint inhibitor myocarditis risk assessment scale multidisciplinary diagnosis |
| url | https://www.c-jcm.com/article/doi/10.12025/j.issn.1008-6358.2025.20250469 |
| work_keys_str_mv | AT yanandai developmentandvalidationofamultidisciplinaryriskassessmentscaleforimmunecheckpointinhibitorassociatedmyocarditis AT yuanliu developmentandvalidationofamultidisciplinaryriskassessmentscaleforimmunecheckpointinhibitorassociatedmyocarditis AT yuchenxu developmentandvalidationofamultidisciplinaryriskassessmentscaleforimmunecheckpointinhibitorassociatedmyocarditis AT qingqingcai developmentandvalidationofamultidisciplinaryriskassessmentscaleforimmunecheckpointinhibitorassociatedmyocarditis AT yanwang developmentandvalidationofamultidisciplinaryriskassessmentscaleforimmunecheckpointinhibitorassociatedmyocarditis AT yuhongzhou developmentandvalidationofamultidisciplinaryriskassessmentscaleforimmunecheckpointinhibitorassociatedmyocarditis AT leileicheng developmentandvalidationofamultidisciplinaryriskassessmentscaleforimmunecheckpointinhibitorassociatedmyocarditis AT junboge developmentandvalidationofamultidisciplinaryriskassessmentscaleforimmunecheckpointinhibitorassociatedmyocarditis |